---
figid: PMC8002185__cancers-13-01191-g003
figlink: pmc/articles/PMC8002185/figure/cancers-13-01191-f003/
number: F3
caption: Serine/glycine biosynthesis pathway activation in tumor treatment resistance.
  The response to targeted therapies in tumors with abnormal activation of RAS–RAF–MEK–ERK
  pathway has been associated with increased expression of serine/glycine biosynthesis
  genes, which might be induced by oncogenic drivers such as EGFRL858R and KRASG12D
  via ATF4 and NFR2, respectively. In addition, serine/glycine biosynthesis pathway
  hyperactivation has been linked to the resistance to chemotherapeutic drugs, e.g.,
  doxorubicin, carboplatin, pemetrexed, or 5-fluorouracil in breast, lung, and colorectal
  cancer (CRC), the proteasome inhibitor bortezomib in multiple myeloma, as well as
  HIF2α antagonists in renal cell carcinoma.
pmcid: PMC8002185
papertitle: Linking Serine/Glycine Metabolism to Radiotherapy Resistance.
reftext: Anaís Sánchez-Castillo, et al. Cancers (Basel). 2021 Mar;13(6):1191.
pmc_ranked_result_index: '9995'
pathway_score: 0.9561155
filename: cancers-13-01191-g003.jpg
figtitle: Serine/glycine biosynthesis pathway activation in tumor treatment resistance
year: '2021'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8002185__cancers-13-01191-g003.html
  '@type': Dataset
  description: Serine/glycine biosynthesis pathway activation in tumor treatment resistance.
    The response to targeted therapies in tumors with abnormal activation of RAS–RAF–MEK–ERK
    pathway has been associated with increased expression of serine/glycine biosynthesis
    genes, which might be induced by oncogenic drivers such as EGFRL858R and KRASG12D
    via ATF4 and NFR2, respectively. In addition, serine/glycine biosynthesis pathway
    hyperactivation has been linked to the resistance to chemotherapeutic drugs, e.g.,
    doxorubicin, carboplatin, pemetrexed, or 5-fluorouracil in breast, lung, and colorectal
    cancer (CRC), the proteasome inhibitor bortezomib in multiple myeloma, as well
    as HIF2α antagonists in renal cell carcinoma.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - KRAS
  - BRAF
  - ARAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - PHGDH
  - ATF4
  - PSAT1
  - MYC
  - PSPH
  - SHMT1
  - SHMT2
  - Erlotinib
  - Vemurafenib
  - Sorafenib
  - U0126
  - Doxorubicin
  - Bortezomib
  - Carboplatin
  - 5-Fluorouracil
genes:
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: МЕКН
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕКН
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PHGDH
  symbol: PHGDH
  source: hgnc_symbol
  hgnc_symbol: PHGDH
  entrez: '26227'
- word: ATF4
  symbol: ATF4
  source: hgnc_symbol
  hgnc_symbol: ATF4
  entrez: '468'
- word: PSAT1
  symbol: PSAT1
  source: hgnc_symbol
  hgnc_symbol: PSAT1
  entrez: '29968'
- word: MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: PSPH
  symbol: PSPH
  source: hgnc_symbol
  hgnc_symbol: PSPH
  entrez: '5723'
- word: SHMT1/2
  symbol: SHMT1
  source: hgnc_symbol
  hgnc_symbol: SHMT1
  entrez: '6470'
- word: SHMT1/2
  symbol: SHMT2
  source: hgnc_symbol
  hgnc_symbol: SHMT2
  entrez: '6472'
chemicals:
- word: Erlotinib
  source: MESH
  identifier: C400278
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: U0126
  source: MESH
  identifier: C113580
- word: Doxorubicin
  source: MESH
  identifier: D004317
- word: Bortezomib
  source: MESH
  identifier: C400082
- word: Carboplatin
  source: MESH
  identifier: D016190
- word: 5-Fluorouracil
  source: MESH
  identifier: D005472
diseases: []
figid_alias: PMC8002185__F3
redirect_from: /figures/PMC8002185__F3
figtype: Figure
---
